[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412719":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HR+\u002FHER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)",null,"Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)",[13],"Drug: palbociclib",{"label":15,"type":10,"description":16,"interventionNames":17},"HR+\u002FHER2- locally advanced or MBC cancer in combination with fulvestrant","Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","palbociclib","patients on palbociclib combination treatment",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"Pfizer Sweden","RECRUITING","Sollentuna","Sweden","SE",{"type":41,"coordinates":42},"Point",[43,44],17.95093,59.42804,{"lat":44,"lon":43},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100412719","swedish-ibrance-registries-insights-siri-100412719",false,"NCT04654208","Swedish Ibrance Registries Insights (SIRI)","Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)","SIRI","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)\n2. Age ≥18 years at index date\n\nExclusion Criteria:\n\nThere are no exclusion criteria","ALL","18 Years",{"count":59,"type":60},1500,"ESTIMATED","OBSERVATIONAL","The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.",[64],"Malignant Neoplasm of Breast",[66],"metastatic breast cancer (MBC)","2026-03-29",{"date":69,"type":70},"2026-03-31","ACTUAL",{"date":72,"type":70},"2020-12-15",{"date":74,"type":60},"2026-05-31",{"name":5,"class":6},1]